AU Patent

AU2016282674B2 — Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors

Assigned to Janssen Biotech Inc · Expires 2022-01-13 · 4y expired

What this patent protects

The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.

USPTO Abstract

The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: AU2016282674B2
Jurisdiction: AU
Classification: —
Expires: 2022-01-13
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Biotech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.